Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Publication of Pricing Supplements

14th Apr 2026 17:49

RNS Number : 4720A
The Democratic Republic of Congo
14 April 2026
 

Publication of Pricing Supplements 

The Democratic Republic of the Congo

Acting through the Ministry of Finance

 

The following pricing supplements (together, the "Pricing Supplements") are available for viewing:

1. Pricing Supplement dated 14 April 2026 in relation to the issue of U.S.$600,000,000 8.750 per cent Amortising Notes due 2032 by the Democratic Republic of the Congo, acting through the Ministry of Finance (the "Issuer") under the Issuer's Global Medium Term Note Programme (the "Programme"); and

2. Pricing Supplement dated 14 April 2026 in relation to the issue of U.S.$650,000,000 9.500 per cent Amortising Notes due 2037 by the Issuer under the Programme.

To view the full document, please paste the following URL into the address bar of your browser:

http://www.rns-pdf.londonstockexchange.com/rns/4720A_1-2026-4-14.pdf

http://www.rns-pdf.londonstockexchange.com/rns/4720A_2-2026-4-14.pdf

For further information, please contact:  

The Democratic Republic of the Congo, acting through the Ministry of Finance

Kinshasa Financial Centre

Intersection of Avenue des Héros & Avenue des Ambassadeurs

Kinshasa Gombe

The Democratic Republic of the Congo

Disclaimer - Intended Addressees

The Pricing Supplements referred to above must be read in conjunction with the base offering circular (the "Base Offering Circular") in respect of the Programme for the purposes of the Prospectus Rules: Admission to Trading on a Regulated Market sourcebook.

Please note that the information contained in the Pricing Supplements and the Base Offering Circular may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Pricing Supplements and/or the Base Offering Circular) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Pricing Supplements and/or the Base Offering Circular is not addressed. Prior to relying on the information contained in the Pricing Supplements and/or the Base Offering Circular you must ascertain from the Pricing Supplements and/or the Base Offering Circular whether or not you are part of the intended addressees of the information contained therein. 

In particular, the Pricing Supplements do not constitute an offer to sell or the solicitation of an offer to buy securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities law of any such jurisdiction. The securities referred to in the Pricing Supplements have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act, and the rules and regulations thereunder. The Issuer does not intend to register any of the securities referred to in the Pricing Supplements in the United States or to conduct a public offering of the securities referred to in the Pricing Supplements in the United States or elsewhere.

Your right to access this service is conditional upon complying with the above requirement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PFTAKQBQABKDAQD
FTSE 100 Latest
Value10,609.06
Change26.10